BLCM — Bellicum Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $0.95m
- -$4.96m
- $1.50m
- 14
- 70
- 20
- 26
Annual income statement for Bellicum Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.12 | 7.14 | 0.5 | 6.2 | 1.5 |
| Cost of Revenue | |||||
| Gross Profit | 0.684 | — | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 96.6 | 94.5 | 52.1 | 31.1 | 28.5 |
| Operating Profit | -95.5 | -87.4 | -51.6 | -24.9 | -27 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -98 | -112 | -7.72 | -9.71 | -25 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -98 | -112 | -7.72 | -9.71 | -25 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -98 | -112 | -7.72 | -9.71 | -25 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -98 | -112 | -7.72 | -9.71 | -25 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -24.4 | -23.6 | -1.78 | -0.802 | -0.81 |